Argenica Therapeutics Limited (ASX: AGN) - Share Price

Current share price for AGN : $0.155 0.005 (3.33%)⁺

Argenica Therapeutics Limited (AGN), an ASX-listed company, is a Company engaged in research and development of a neuroprotective therapeutic drug. Its neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).

AGN General Information ⁺

ASX Code	AGN
Website	N/A
Industry/Sector	Pharmaceuticals
Market Cap ($M)	19
AGN Share Price	$0.155
Day High	$0.155
Day Low	$0.150
Last Close	$0.150
AGN Share Price Movement	$0.01 ( 3.33% )

Prices as at 16:40, 31 Jul 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

How AGN Plays a Part in Australian ETF Strategies

Argenica Therapeutics Limited (AGN) is held across 19 ETFs spanning strategies that include pharmaceuticals exposure . Its weighting in those funds means performance can have an outsized influence - when AGN moves, funds like VVLU, VLUE, VEQ, DGSM and IEU that hold it can move with it.

For more concentrated exposure, ETFs such as VVLU (Vanguard Global Value Equity Active ETF (Managed Fund)) allocate about 0.1% to AGN , while the average exposure across all 19 ETFs that hold it is around 0% .

Top ETF holdings

Vanguard Global Value Equity Active ETF (Managed Fund) (VVLU) ~ 0.1%
VanEck MSCI International Value ETF (VLUE) ~ 0.1%
Vanguard FTSE Europe Shares ETF (VEQ) ~ 0.1%
Dimensional Global Small Company Trust - Active ETF (DGSM) ~ 0.1%
iShares Europe ETF (IEU) ~ 0.1%

AGN Direct vs. ETF Alternatives

How does holding Argenica Therapeutics Limited (AGN) shares directly compare to ETFs that include it?

	AGN Direct	VVLU ASX	VLUE ASX	VEQ ASX	DGSM ASX	IEU ASX
Holdings	1 company	1,068 holdings	250 holdings	1,192 holdings	4,386 holdings	359 holdings
Risk Profile	High	Medium	Medium	Medium	Medium	High
Asset Class	Share	Equities	Equities	Equities	Equities	Equities
Annual Cost	Brokerage only	0.28% p.a.	0.4% p.a.	0.35% p.a.	0.55% p.a.	0.59% p.a.
Approx. Yield	-	11.59%	17.81%	2.17%	3.91%	8.37%
Latest Franking	-	0%	0%	0%	0%	0%

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not AGN's direct yield.

Argenica Therapeutics Limited (AGN) ETFs

19 ETFs hold Argenica Therapeutics Limited (AGN).

ETF	AGN Weight	MER	Yield
Vanguard Global Value Equity Active ETF (Managed Fund) (VVLU)	0.1%	0.28%	11.59%
VanEck MSCI International Value ETF (VLUE)	0.1%	0.4%	17.81%
Vanguard FTSE Europe Shares ETF (VEQ)	0.1%	0.35%	2.17%
Dimensional Global Small Company Trust - Active ETF (DGSM)	0.1%	0.55%	3.91%
iShares Europe ETF (IEU)	0.1%	0.59%	8.37%
iShares MSCI World ex Australia Value ETF (IVLU)	0.1%	0.25%	-
iShares Edge MSCI World Multifactor ETF (WDMF)	0.1%	0.35%	3.5%
Dimensional Global Value Trust - Active ETF (DGVA)	0%	0.4%	3.72%
Vanguard All-World ex-US Shares Index ETF (VEU)	0%	0.02%	2.24%
iShares Core MSCI World Ex Australia ESG Leaders (AUD Hedged) ETF (IHWL)	0%	0.12%	5.67%

Argenica Therapeutics Limited (AGN) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Argenica Therapeutics Limited (AGN) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Argenica Therapeutics Limited (AGN) price-sensitive announcements

AGN - Quarterly Activities/Appendix 4C Cash Flow Report

Argenica Therapeutics Limited, an Australian biotechnology company, is focused on developi

Argenica Therapeutics Limited (AGN)
24 Jul 2026 | 9:18 AM

AGN - ARG007 Shows Significant Neuroprotection in Concussion Study

Argenica Therapeutics Limited announced promising preclinical efficacy data for its drug c

Argenica Therapeutics Limited (AGN)
16 Jul 2026 | 8:27 AM

AGN - ARG007 (Xaranetide) Completes All Three FDA Requested Assays

Argenica Therapeutics Limited has announced the successful completion of the final FDA req

Argenica Therapeutics Limited (AGN)
11 Jun 2026 | 8:33 AM

AGN - WHO Confirms Xaranetide as INN for ARG-007

Argenica Therapeutics Limited, an Australian biotechnology company, announced that the Wor

Argenica Therapeutics Limited (AGN)
10 Jun 2026 | 8:19 AM

Argenica Therapeutics Limited (AGN) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID	Health Care	$20	Investor Presentation - Techknow Conference	27 Jul 2026 9:13AM	$0.155	$0.155	fallen by 0%
Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID	Health Care	$20	Quarterly Activities/Appendix 4C Cash Flow Report	24 Jul 2026 9:18AM	$0.150	$0.155	risen by 3.33%
Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID	Health Care	$20	ARG007 Shows Significant Neuroprotection in Concussion Study	16 Jul 2026 8:27AM	$0.140	$0.155	risen by 10.71%
Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID	Health Care	$20	Investor Webinar	11 Jun 2026 8:33AM	$0.110	$0.155	risen by 40.91%
Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID	Health Care	$20	Investor Presentation	11 Jun 2026 8:33AM	$0.110	$0.155	risen by 40.91%
Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID	Health Care	$20	ARG007 (Xaranetide) Completes All Three FDA Requested Assays	11 Jun 2026 8:33AM	$0.110	$0.155	risen by 40.91%

AGN Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$7.17	-$5.60	6.40%	0.00%	0.0%
2024A	-$5.48	-$5.30	-4.00%	0.00%	0.0%
2023A	-$4.82	-$5.50	-0.50%	0.00%	0.0%

AGN Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
Argenica Therapeutics Limited (AGN)	$19M	0.0644	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Clarity Pharmaceuticals Ltd (CU6)	$783M	0.3002	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,216M	-0.7857	0.0743	1.2000	75.1182	69.9200	31.7818	0.00%	0.00%	0.00%

AGN Directors

Name	Position	Start Date
Dr Liz Dallimore	Chief Executive Officer, Managing Director	4 Apr 2022
Dr Jeannie(Jeannette) Joughin	Non-Executive Director	2 Dec 2024
Dr Mark Etherton	Non-Executive Director	17 Sep 2024

Argenica Therapeutics Limited (AGN) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
14 Aug 2024	ANGUS, Dianne	Issued	Options	500,000	$0.275	$137,727.000
8 Aug 2024	BUDGE, Terrence (Terry)	Cancelled	Options	181,818	$1.000	$181,818.000
8 Aug 2024	DALLIMORE, Liz	Cancelled	Options	909,091	$0.825	$750,000.000

See all changes in directors' interest & trades for Argenica Therapeutics Limited (AGN) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

AGN Management

Name	Position
Emma Waldon	Chief Financial Officer,Company Secretary

AGN Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Argenica Therapeutics Limited (AGN). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
7,835,976 (6.10%)	Neil Delroy

AGN Calendar of Events

Date	Event
10 February 2027	Report (Interim)
27 August 2026	Report (Annual)
27 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us